Combination phenylbutyrate/gemcitabine therapy effectively inhibits <it>in vitro </it>and <it>in vivo </it>growth of NSCLC by intrinsic apoptotic pathways

Combination phenylbutyrate/gemcitabine therapy effectively inhibits <it>in vitro </it>and <it>in vivo </it>growth of NSCLC by intrinsic apoptotic pathways

<p>Abstract</p> <p>Background</p> <p>Standard chemotherapy protocols in NSCLC are of limited clinical benefit. Histone deacetylase (HDAC) inhibitors represent a new strategy in human cancer therapy. In this study the combination of the HDAC inhibitor phenylbutyrate (PB)...

Full description

Bibliographic Details
Main Authors: Schniewind Bodo, Heintz Kirsten, Kurdow Roland, Ammerpohl Ole, Trauzold Anna, Emme Doris, Dohrmann Peter, Kalthoff Holger
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2006-11-01
Series:Journal of Carcinogenesis
Online Access:http://www.carcinogenesis.com/content/5/1/25

Internet

http://www.carcinogenesis.com/content/5/1/25

Similar Items